ATM and neoplasm: came to a similar conclusion that the ATM-CHK2 axis could be a potential target during tumor therapy and that selective inhibition of the checkpoint signaling axis ATM-CHK2 could activate the body’s intrinsic innate immunity and enhance ICI therapeutic efficacy, which has been demonstrated in ARID1A-deficient tumors (85).